Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400PRNewsWire · Oct 8, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPRNewsWire · Oct 1, 2026
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 TranscriptSeeking Alpha · Sep 22, 2026
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500PRNewsWire · Sep 22, 2026
Biotech Options Buzz: UTHR, NMRA, EWTXSchaeffers Research · Sep 18, 2026
91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLCDefense World · Sep 11, 2026Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.47 | -$0.53 | Miss |
| May 7, 2026 | -$0.50 | -$0.46 | Beat |
| Feb 26, 2026 | -$0.43 | -$0.47 | Miss |
| Nov 6, 2025 | -$0.40 | -$0.39 | Beat |
| Aug 7, 2025 | -$0.42 | -$0.34 | Beat |
| May 8, 2025 | -$0.45 | -$0.43 | Beat |